 1.2. Secondary Objectives 1. To evaluate the efficacy of B244 in participants with mild to moderate acne vulgaris from baseline to weeks 2, 4, 8, and 16: i Reduction in inflammatory and non-inflammatory lesion count ii IGA success iii Improvement in patient reported quality of life score using the Skindex-16 questionnaire 